Literature DB >> 16815577

Blood substitutes based on nanobiotechnology.

Thomas Ming Swi Chang1.   

Abstract

Stimulated by concerns of potential infective agents in donated blood, commercial enterprises have attempted to develop blood substitutes since the 1900s. After several years of development, a few of the many leads are showing promise. In this article, nanobiotechnological approaches that are now in phase III clinical trials are reviewed, followed by a discussion of how important basic knowledge gained is being used to develop new generations of blood substitutes based on nanobiotechnology.

Mesh:

Substances:

Year:  2006        PMID: 16815577     DOI: 10.1016/j.tibtech.2006.06.005

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  10 in total

1.  The immunological properties of stroma-free polyhemolysate containing catalase and superoxide dismutase activities prepared by polymerized bovine stroma-free hemolysate.

Authors:  Hongli Zhu; Qianqian Du; Chao Chen; Thomas Ming Swi Chang
Journal:  Artif Cells Blood Substit Immobil Biotechnol       Date:  2010-04

2.  2017 Military Supplement: Hemoglobin-based Oxygen Carriers: Current State-of-the-Art and Novel Molecules.

Authors:  Anirban Sen Gupta
Journal:  Shock       Date:  2017-09-29       Impact factor: 3.454

3.  Development of a method to produce hemoglobin in a bioreactor culture of Escherichia coli BL21(DE3) transformed with a plasmid containing Plesiomonas shigelloides heme transport genes and modified human hemoglobin genes.

Authors:  B J Z Smith; P Gutierrez; E Guerrero; C J Brewer; D P Henderson
Journal:  Appl Environ Microbiol       Date:  2011-07-29       Impact factor: 4.792

Review 4.  Bio-inspired nanomedicine strategies for artificial blood components.

Authors:  Anirban Sen Gupta
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-03-15

5.  Quantitative analysis of hemoglobin content in polymeric nanoparticles as blood substitutes using Fourier transform infrared spectroscopy.

Authors:  Xiaoqian Shan; Ligen Chen; Yuan Yuan; Changsheng Liu; Xiaolan Zhang; Yan Sheng; Feng Xu
Journal:  J Mater Sci Mater Med       Date:  2010-01       Impact factor: 3.896

6.  Enhancement of recombinant hemoglobin production in Escherichia coli BL21(DE3) containing the Plesiomonas shigelloides heme transport system.

Authors:  D M Villarreal; C L Phillips; A M Kelley; S Villarreal; A Villaloboz; P Hernandez; J S Olson; D P Henderson
Journal:  Appl Environ Microbiol       Date:  2008-08-01       Impact factor: 4.792

7.  Site-selective glycosylation of hemoglobin on Cys beta93.

Authors:  Yalong Zhang; Veer S Bhatt; Guoyong Sun; Peng G Wang; Andre F Palmer
Journal:  Bioconjug Chem       Date:  2008-11-19       Impact factor: 4.774

8.  Low modulus biomimetic microgel particles with high loading of hemoglobin.

Authors:  Kai Chen; Timothy J Merkel; Ashish Pandya; Mary E Napier; J Christopher Luft; Will Daniel; Sergei Sheiko; Joseph M DeSimone
Journal:  Biomacromolecules       Date:  2012-08-17       Impact factor: 6.988

9.  Blood substitutes--the polyheme trials.

Authors:  Sameer S Apte
Journal:  Mcgill J Med       Date:  2008-01

Review 10.  Artificial Blood Substitutes: First Steps on the Long Route to Clinical Utility.

Authors:  Samira Moradi; Ali Jahanian-Najafabadi; Mehryar Habibi Roudkenar
Journal:  Clin Med Insights Blood Disord       Date:  2016-10-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.